Eli Lilly To Launch Diabetes Drug Byetta In China
This article was originally published in PharmAsia News
Executive Summary
Eli Lilly has received imported drug approval from China's State FDA for its diabetes drug Byetta (exenatide injection), which is expected to be officially launched in China in the second half of this year. Local experts said the drug provides a new option to diabetes patients who cannot achieve good glycemic control with oral anti-diabetic drugs but are averse to insulin injection. Fixed doses of Byetta are easily injected twice daily with a pen device, dispensing with the current inconvenient method of insulin dosage adjustment according to blood sugar levels. Besides controlling blood sugar, the drug also helps patients lose weight; weight gain is a problem plaguing most diabetics. (Click here for more - Chinese Language)